Association between src-kinases and the polyoma virus oncogene middle T-antigen requires PP2A and a specific sequence

H R Glover1, C E Brewster, S M Dilworth

  • 1Department of Metabolic Medicine, Imperial College School of Medicine, London, UK.

Oncogene
|August 10, 1999
PubMed

Insights

Polyoma virus middle T-antigen (MT) transformation involves binding src-family kinases. This study reveals PP2A is essential for the MT-src complex, with specific MT motifs mediating kinase interaction via a novel, non-phosphorylation-dependent mechanism.

Area of Science:

  • Molecular Biology
  • Virology
  • Oncogenesis

Background:

  • Polyoma virus middle T-antigen (MT) is a potent oncogene that mimics tyrosine kinase-associated growth factor receptors.
  • MT induces cell transformation by interacting with and activating src-family kinases.
  • The precise mechanism of MT interaction with src-kinases remains incompletely understood.

Purpose of the Study:

  • To elucidate the mechanism by which polyoma virus middle T-antigen (MT) interacts with and activates src-family kinases.
  • To investigate the role of protein phosphatase 2A (PP2A) in the MT-src complex.
  • To identify specific regions and motifs within MT critical for src-kinase interaction.

Main Methods:

  • Biochemical assays to analyze protein-protein interactions within the MT-src complex.
  • Analysis of MT mutants to determine the role of specific amino acid motifs in kinase binding.
  • Investigation of the requirement for phosphatase activity in MT-src complex formation.

Main Results:

  • The MT-src complex contains stoichiometric amounts of PP2A, indicating PP2A is a necessary component.
  • Specific motifs (basic region followed by serine/threonine) in the MT 185-210 region are crucial for src-kinase interaction but not PP2A binding.
  • The spacing within these motifs and the interaction mechanism with src-kinases do not require MT phosphorylation.

Conclusions:

  • PP2A is an integral and essential component of the MT-src oncogenic complex.
  • MT interacts with src-kinases through a novel mechanism involving specific sequence motifs that does not rely on tyrosine phosphorylation.
  • These findings provide new insights into the molecular mechanisms of viral oncogenesis and kinase regulation.

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...